3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Mesothelioma
1
Lung Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
belinostat
2
Pemetrexed
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
tocilizumab
1
sargramostim
1
ribociclib
1
rebastinib
1
enzalutamide
1
entinostat
1
durvalumab
1
cemiplimab
1
avelumab
1
atezolizumab
1
abemaciclib
1
Valacyclovir
1
Surgical Procedures, Operative
1
Sorafenib
1
Sirolimus
1
Quality of Life
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Plicamycin
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Midazolam
1
Microarray Analysis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Valacyclovir
×
Other solid neoplasm
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled